HTHT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HTHT looks like a good buy for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has constructive analyst support, improving operating momentum, and no major insider or hedge-fund selling pressure. While the technicals are only neutral-to-slightly soft in the very short term, the broader picture is supportive enough to justify buying now rather than waiting, especially since the investor is impatient and wants exposure to a long-term winner.
Current pre-market price is 45.08, up 0.85%, with the stock trading near its pivot level of 44.848. MACD histogram is -0.138, still below zero but contracting, which suggests downside momentum is fading. RSI_6 at 40.275 is neutral and not oversold. Moving averages are converging, indicating a potential base-building phase rather than a strong downtrend. Support is at 43.168 and 42.129, while resistance sits at 46.529 and 47.568. The short-term setup is not a breakout yet, but it is stable and acceptable for a long-term entry.
Analysts have become increasingly constructive, with Citi keeping Buy and adding a 30-day upside catalyst watch, Benchmark raising its target to $60, Macquarie raising to $62, and UBS upgrading to Buy. Recent commentary highlights solid Q4 results, improving RevPAR trends, margin expansion from the asset-light strategy, and 2026 guidance for about 1,600 new hotel openings. News also shows Rovida Investment Management initiated a new stake with a sizable purchase of 200,000 shares, which is a positive ownership signal.
The technical setup is not strongly bullish right now: MACD is still negative, RSI is only neutral, and similar candlestick pattern analysis suggests weak near-term returns. Hedge funds and insiders are both neutral with no meaningful positive trading trend. There is also no strong near-term catalyst from congress trading or major influential selling/buying activity beyond the recent institutional stake addition.
Latest quarter was Q4 2025. The company reported revenue up 8.3% year over year and adjusted EBITDA up 83% year over year, both ahead of consensus. Management’s outlook is described as increasingly constructive, with RevPAR recovery continuing and overseas RevPAR up 7.4% year over year. The latest quarter points to clear growth acceleration and margin expansion, which is a strong sign for long-term investors.
Wall Street sentiment is clearly positive. Citi maintained Buy with a $59 target and added an upside 30-day catalyst watch. Benchmark lifted its target to $60 from $52 and kept Buy. Macquarie raised its target to $62 from $59 and kept Outperform. UBS upgraded the stock to Buy from Neutral with a $62.40 target. The pros view is that RevPAR is improving, margins are expanding, and the stock remains below peer valuation. The main con is that the current technical trend is not yet strongly impulsive, so near-term upside may be gradual rather than immediate.
